Akari Therapeutics amended its Securities Purchase Agreement with investors to combine the second and third closings of its private placement into a single closing on June 26, 2026. The company issued the remaining 980,395 ADSs (or prefunded warrants) due under the deal, following the initial closing on May 27, 2026, for a total offering of 1,470,588 ADSs. Series H, I, and J warrants will be delivered upon receipt of shareholder approval at the June 30, 2026 annual meeting.
Agreement details:
- Agreement type: Amendment to Securities Purchase Agreement for private placement of ADSs and warrants
- Counterparty: Certain investors
- Signed / Effective: Jun 23 2026 / Jun 23 2026
- Duration / Termination: At will
- Reason: Consolidate closings and complete financing
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.